(-0.16%) 5 204.25 points
(-0.13%) 39 144 points
(-0.23%) 18 145 points
(0.46%) $79.35
(0.32%) $2.19
(0.01%) $2 322.50
(1.05%) $27.89
(0.67%) $991.20
(0.08%) $0.931
(0.18%) $10.91
(0.11%) $0.801
(-0.01%) $91.73
-1.26% INR 5 980.20
Live Chart Being Loaded With Signals
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments...
Stats | |
---|---|
Today's Volume | 187 150 |
Average Volume | 375 563 |
Market Cap | 995.49B |
EPS | INR0 ( 2024-05-06 ) |
Next earnings date | ( INR0 ) 2024-07-26 |
Last Dividend | INR40.00 ( 2023-07-11 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 19.07 |
ATR14 | INR4.04 (0.07%) |
Volume Correlation
Dr. Reddy's Laboratories Correlation
10 Most Positive Correlations | |
---|---|
SETF10GILT.NS | 0.933 |
ASHIANA.NS | 0.919 |
MOGSEC.NS | 0.915 |
ADORWELD.NS | 0.905 |
BHARATWIRE.NS | 0.903 |
IZMO.NS | 0.898 |
BAJAJ-AUTO.NS | 0.893 |
GTNTEX.NS | 0.884 |
CYIENT.NS | 0.883 |
MASPTOP50.NS | 0.882 |
10 Most Negative Correlations | |
---|---|
STARTECK.NS | -0.898 |
SUNCLAYLTD.NS | -0.875 |
SCI.NS | -0.87 |
TEAMLEASE.NS | -0.856 |
ORTINLAB.NS | -0.853 |
MOHOTAIND.NS | -0.851 |
EASTSILK.NS | -0.851 |
ROLTA.NS | -0.844 |
CLNINDIA.NS | -0.844 |
GENESYS.NS | -0.839 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dr. Reddy's Laboratories Correlation - Currency/Commodity
Dr. Reddy's Laboratories Financials
Annual | 2022 |
Revenue: | INR245.88B |
Gross Profit: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Revenue: | INR245.88B |
Gross Profit: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Revenue: | INR214.39B |
Gross Profit: | INR113.84B (53.10 %) |
EPS: | INR142.08 |
FY | 2021 |
Revenue: | INR189.72B |
Gross Profit: | INR103.08B (54.33 %) |
EPS: | INR103.94 |
Financial Reports:
No articles found.
Dr. Reddy's Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR60.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR40.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR2.50 | 2003-08-08 |
Last Dividend | INR40.00 | 2023-07-11 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | INR363.00 | -- |
Avg. Dividend % Per Year | 0.62% | -- |
Score | 3.63 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.28 | |
Div. Directional Score | 8.85 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR40.00 | 1.93% |
2019 | INR20.00 | 0.77% |
2020 | INR25.00 | 0.87% |
2021 | INR25.00 | 0.48% |
2022 | INR60.00 | 1.24% |
2023 | INR40.00 | 0.94% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RAMCOCEM.NS | Dividend Junior | 2023-08-02 | Annually | 23 | 0.21% | |
KKCL.NS | Dividend Knight | 2023-05-11 | Semi-Annually | 19 | 1.67% | |
ENIL.NS | Dividend Junior | 2023-09-15 | Annually | 12 | 0.39% | |
ALICON.NS | Dividend Junior | 2023-09-13 | Annually | 18 | 0.25% | |
SWARAJENG.NS | Dividend Knight | 2023-07-06 | Annually | 23 | 2.81% | |
NDRAUTO.NS | Dividend Junior | 2023-07-12 | Annually | 4 | 0.59% | |
ICICIGI.NS | Dividend Junior | 2023-06-12 | Annually | 8 | 0.36% | |
CENTENKA.NS | Dividend Junior | 2023-08-11 | Annually | 22 | 1.85% | |
RUPA.NS | Dividend Junior | 2023-08-01 | Annually | 13 | 0.60% | |
LINCOLN.NS | Dividend Junior | 2023-09-15 | Annually | 9 | 0.32% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.192 | 1.500 | 6.15 | 9.23 | [0 - 0.5] |
returnOnAssetsTTM | 0.140 | 1.200 | 5.33 | 6.40 | [0 - 0.3] |
returnOnEquityTTM | 0.209 | 1.500 | 8.79 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.127 | -1.000 | 8.73 | -8.73 | [0 - 1] |
currentRatioTTM | 2.55 | 0.800 | 2.26 | 1.809 | [1 - 3] |
quickRatioTTM | 1.800 | 0.800 | 4.12 | 3.30 | [0.8 - 2.5] |
cashRatioTTM | 0.0784 | 1.500 | -0.675 | -1.013 | [0.2 - 2] |
debtRatioTTM | 0.0532 | -1.500 | 9.11 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 44.26 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0741 | -1.500 | 9.70 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.641 | 1.000 | 2.66 | 2.66 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.240 | 1.000 | 7.20 | 7.20 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.70 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.728 | 0.800 | 8.48 | 6.79 | [0.5 - 2] |
Total Score | 11.41 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.18 | 1.000 | 8.16 | 0 | [1 - 100] |
returnOnEquityTTM | 0.209 | 2.50 | 9.22 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.665 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.127 | 1.500 | 8.73 | -8.73 | [0 - 1] |
pegRatioTTM | 0.211 | 1.500 | -1.929 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.198 | 1.000 | 7.56 | 0 | [0.1 - 0.5] |
Total Score | 6.28 |
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators